2008 to 2020 Saw Increase in Survival for Advanced Prostate Cancer
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
THURSDAY, Oct. 19, 2023 -- During a time period with improvements in treatment of advanced prostate cancer, there was a simultaneous clinically meaningful increase in mean survival for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to a study published online Oct. 2 in JAMA Network Open.
Christian Corsini, M.D., from Uppsala University in Sweden, and colleagues examined changes in survival with the introduction of doublet therapy for advanced prostate cancer. The analysis included data from 11,382 men with de novo mCSPC identified in the Prostate Cancer data Base Sweden (2008 to 2020).
The researchers found a shift toward less advanced prostate cancer during the study period with a decrease in median prostate-specific antigen at diagnosis in men with mCSPC from 145 ng/mL to 107 ng/mL. There was an increase seen in upfront treatment with doublet therapy from 1 percent in 2016 to 44 percent in 2020. In addition, there was an increase noted in the adjusted five-year overall survival, from 26 percent in 2008 to 2012 to 35 percent in 2017 to 2020. An increase in mean survival of six months during the first five years after diagnosis was also observed (2.7 years from 2008 to 2012 to 3.2 years from 2017 to 2020).
"Between 2008 and 2020, mean survival increased with six months after five years of follow-up in all individuals with de novo mCSPC, taking changes in age, comorbidity, and cancer characteristics into account, supporting that doublet therapy is effective in clinical practice on a population basis," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
AI-Assisted Contours Superior to Cognitively Defined Prostate Cancer Contours
WEDNESDAY, July 3, 2024 -- Artificial intelligence (AI)-assisted definition of prostate cancer contours reduces underestimation of the extent of prostate cancer, according to a...
Black Patients More Likely to Experience MACE After ADT for Prostate Cancer
THURSDAY, June 20, 2024 -- Black patients are more likely to experience adverse cardiovascular outcomes after systemic androgen deprivation therapy (ADT) for prostate cancer...
Higher County-Level Prostate Cancer Screening Tied to Better Outcomes
FRIDAY, June 7, 2024 -- Higher county-level prevalence of prostate-specific antigen (PSA) screening is associated with lower odds of advanced disease, all-cause mortality, and...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.